Literature DB >> 30324612

Cytotoxic activity and molecular targets of atractylodin in cholangiocarcinoma cells.

Vivek B Mathema1, Wanna Chaijaroenkul1, Kesara Na-Bangchang1.   

Abstract

OBJECTIVES: To evaluate the cytotoxic activity of atractylodin and its potential effects on heme oxygenase (HO)-1 production, STAT1/3 phosporylation and major NF-κB protein expression in the cholangiocarcinoma-associated cell line CL-6.
METHODS: Standard MTT assay was used for accessing antiproliferative activity on CL-6 cells. Normal human embryonic fibroblast (OUMS) cell was taken as control cell line. Colony formation and wound healing assay were conducted to access the effects of atractylodin on cell proliferation and directional migration activity of CL-6 cells. Western blot was used for evaluating levels of protein expression and phosphorylation. KEY
FINDINGS: Atractylodin exhibited selective cytotoxicity towards CL-6 as compared with OUMS with IC50 of 216.8 (212.4-233.8) and 351.2 (345.7-359.5) μm [median (range)], respectively. Exposure to the compound dose-dependently inhibited colony formation ability and decreased wound closure potential of CL-6 cells. Atractylodin treatment suppressed HO-1 production in CL-6 cells. It dose-dependently inhibited STAT1/3 protein phosphorylation and moderately inhibited NF-κB (p50), NF-κB (p52), and NF-κB (p65) protein expression in both dose- and time-dependent manner.
CONCLUSIONS: Atractylodin exerts significant cytotoxic activity against CL-6 cells which may be linked to its suppressive effect on HO-1 production, STAT1/3 phosphorylation and expression of key NF-κB proteins.
© 2018 Royal Pharmaceutical Society.

Entities:  

Keywords:  zzm321990Atractylodes lanceazzm321990; CL-6; OUMS; atractylodin; cholangiocarcinoma

Mesh:

Substances:

Year:  2018        PMID: 30324612     DOI: 10.1111/jphp.13024

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Atractylodin Induces Apoptosis and Inhibits the Migration of A549 Lung Cancer Cells by Regulating ROS-Mediated Signaling Pathways.

Authors:  Tong Zhang; Shu-Mei Li; Yan-Nan Li; Jing-Long Cao; Hui Xue; Chang Wang; Cheng-Hao Jin
Journal:  Molecules       Date:  2022-05-05       Impact factor: 4.927

2.  Screening of Molecular Targets of Action of Atractylodin in Cholangiocarcinoma by Applying Proteomic and Metabolomic Approaches.

Authors:  Kanawut Kotawong; Wanna Chaijaroenkul; Sittiruk Roytrakul; Narumon Phaonakrop; Kesara Na-Bangchang
Journal:  Metabolites       Date:  2019-11-01

3.  A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects.

Authors:  Inthuon Kulma; Luxsana Panrit; Tullayakorn Plengsuriyakarn; Wanna Chaijaroenkul; Siriprapa Warathumpitak; Kesara Na-Bangchang
Journal:  BMC Complement Med Ther       Date:  2021-02-12

4.  Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade.

Authors:  Pongsakorn Martviset; Luxsana Panrit; Pathanin Chantree; Phunuch Muhamad; Kesara Na-Bangchang
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

5.  Effect of drought on photosynthesis, total antioxidant capacity, bioactive component accumulation, and the transcriptome of Atractylodes lancea.

Authors:  Aqin Zhang; Mengxue Liu; Wei Gu; Ziyun Chen; Yuchen Gu; Lingfeng Pei; Rong Tian
Journal:  BMC Plant Biol       Date:  2021-06-25       Impact factor: 4.215

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.